

09.00 Introductory Session: Current strategies

Hardik Madlani, Senior VP, Jefferies Healthcare Investment Banking

- Trends and activity in Business Development, M&A and Corporate Development

09.30 What's new in IP

Andrew Wells, Partner, HGF Ltd

- an update on key issues and impact on Business Development contracts including:
 - unitary patent,
 - equivalence,
 - impact of Brexit on IP strategy and other developments

10.30 Asset management: finding the best vehicle for commercialising your assets and deal strategies for partnering

Neil Crabb, CEO, Frontier IP Group plc

- Defining the partnering strategy
- Licensing vs spin out vs SPV - what is really involved
- Current approaches and use of options
- How to work out equity value
- Role of corporate documentation

11.30 Due Diligence Case Study

Martin Cadman, Due Diligence Director, AstraZeneca

12.30 LUNCH

13.30 What's new – an update on Legal aspects in BD Agreements

Luke Kempton, Partner, Gowling WLG (UK) LLP

- Legal updates: Brexit and current issues in agreements
- Latest perspectives on the topical issues today
- GDPR: what do you need in the contract?
- Changes required to accommodate BREXIT

14.30 What's new – an update on Regulatory issues

Bob Clay, Board Director, Topra

- Recent changes at FDA and in Europe
- EMA plan for UK companies and for EU companies, MHRA position is to plan for a hard Brexit.

15.30 Operational aspects: the road map from MA to market

Brian McEwan, Advisor, Cognital Ltd

- Post grant of MA – how does the product get to market?
- Latest perspectives on supply chain management, time frame management and performance issues

16.30 Transitional Service Agreements / Integration Programmes

Stephen Kidner, Chief Scientific Affairs & Operations officer, Alliance Pharma Ltd

- What is included, what issues arise, how to manage issues.
- Operational topics and challenges
- How we need to work for success